TTY Biopharm Company Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	2,798	2,521	2,773	2,621	2,357	2,222
Short-Term Investments	22.6	467.74	309.02	195.54	326.86	372.65
Cash & Short-Term Investments	2,820	2,989	3,082	2,817	2,684	2,595
Cash Growth	-12.81%	-3.02%	9.41%	4.93%	3.44%	1.12%
Accounts Receivable	1,352	1,518	1,354	1,344	1,227	1,138
Other Receivables	33.4	36.46	23.18	28.81	29.68	13.62
Receivables	1,385	1,554	1,377	1,373	1,257	1,151
Inventory	1,406	1,389	1,270	1,096	1,039	955.01
Prepaid Expenses	58.74	-	-	79.02	49.89	46.96
Other Current Assets	516.57	76.88	64.58	6.36	5.37	1.15
Total Current Assets	6,187	6,009	5,793	5,370	5,035	4,749
Property, Plant & Equipment	2,176	2,199	2,246	2,287	2,433	2,519
Long-Term Investments	1,948	2,205	1,940	1,578	1,496	1,432
Goodwill	-	247.9	247.9	-	-	-
Other Intangible Assets	592.44	177.27	123.44	164.01	250.75	124.9
Long-Term Deferred Tax Assets	65.8	65.8	58.52	48.71	47.1	63.72
Other Long-Term Assets	706.61	444.8	453.25	426.94	337.89	407.19
Total Assets	11,676	11,348	10,863	9,875	9,601	9,296
Accounts Payable	298.96	270.78	326.16	294.66	289.4	187.27
Short-Term Debt	500	700	1,200	1,450	1,370	1,711
Current Portion of Long-Term Debt	-	500	400	-	418.85	407.91
Current Portion of Leases	8.72	8.35	0.93	5.86	3.92	7.62
Current Income Taxes Payable	434.15	323.68	228.8	156.97	149.52	150.39
Current Unearned Revenue	31.49	53.7	34.34	14.23	33.13	39.77
Other Current Liabilities	2,348	783.33	672.18	662.02	652.62	547.55
Total Current Liabilities	3,621	2,640	2,862	2,584	2,917	3,052
Long-Term Debt	-	-	100	400	9.6	4.15
Long-Term Leases	6.42	7.4	10.2	3.05	3.04	14.16
Pension & Post-Retirement Benefits	-	17.01	17.54	27.4	40.81	52.6
Long-Term Deferred Tax Liabilities	363.19	363.19	359.24	318.75	305.44	260.52
Other Long-Term Liabilities	286.22	269.3	2.44	35.83	91.03	146.23
Total Liabilities	4,277	3,297	3,352	3,369	3,367	3,529
Common Stock	2,487	2,487	2,487	2,487	2,487	2,487
Additional Paid-In Capital	317.56	317.56	317.04	316.62	312.18	311.88
Retained Earnings	3,751	4,427	3,888	3,182	2,925	2,568
Comprehensive Income & Other	12.98	7.18	58.69	-43.79	-64.78	-198.07
Total Common Equity	6,568	7,238	6,750	5,941	5,658	5,168
Minority Interest	830.33	812.93	760.49	564.8	574.86	599.38
Shareholders' Equity	7,399	8,051	7,511	6,506	6,233	5,767
Total Liabilities & Equity	11,676	11,348	10,863	9,875	9,601	9,296
Total Debt	515.14	1,216	1,711	1,859	1,805	2,145
Net Cash (Debt)	2,305	1,773	1,371	957.65	878.78	450
Net Cash Growth	33.81%	29.36%	43.11%	8.97%	95.28%	6.52%
Net Cash Per Share	8.79	7.11	5.50	3.84	3.53	1.81
Filing Date Shares Outstanding	443.07	248.65	248.65	248.65	248.65	248.65
Total Common Shares Outstanding	443.07	248.65	248.65	248.65	248.65	248.65
Working Capital	2,566	3,369	2,931	2,787	2,118	1,698
Book Value Per Share	14.82	29.11	27.15	23.89	22.76	20.78
Tangible Book Value	5,976	6,813	6,379	5,777	5,408	5,043
Tangible Book Value Per Share	13.49	27.40	25.65	23.23	21.75	20.28
Land	-	902.9	902.9	902.9	902.9	902.9
Buildings	-	1,495	1,479	1,461	1,432	1,420
Machinery	-	1,443	1,446	1,432	1,418	1,359
Construction In Progress	-	71.53	0.59	8.95	77.09	95

Source: S&P Global Market Intelligence. Standard template. Financial Sources.